The first study on the effect of crocodile oil from *Crocodylus siamensis* on hepatic mitochondrial function for energy homeostasis in rats

Kongphop Parunyakul, Krittika Srisuksai, Pitchaya Santativongchai, Urai Pongchaierk, Sumate Ampawong, Phitsanu Tulayakul, and Wirasak Fungfuang

1. Department of Zoology, Faculty of Science, Kasetsart University, Bangkok, Thailand; 2. Bio-Veterinary Sciences (International Program), Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand; 3. Department of Anatomy, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand; 4. Department of Tropical Pathology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 5. Department of Veterinary Public Health, Veterinary Medicine, Kasetsart University, Nakhon Pathom, Thailand.

**Corresponding author:** Wirasak Fungfuang, e-mail: fsciwsf@ku.ac.th

**Co-authors:** KP: kongphop.pa@ku.th, KS: krit_ti_ka@hotmail.com, FS: pitchaya.sant@ku.th, UP: fveturp@ku.ac.th, SA: am_sumate@hotmail.com, PT: fvetpnt@ku.ac.th

**Received:** 14-01-2022, **Accepted:** 11-03-2022, **Published online:** 19-04-2022

**doi:** [www.doi.org/10.14202/vetworld.2022.986-997](http://www.doi.org/10.14202/vetworld.2022.986-997)

**How to cite this article:** Parunyakul K, Srisuksai K, Santativongchai P, Pongchaierk U, Ampawong S, Tulayakul P, Fungfuang W (2022) The first study on the effect of crocodile oil from *Crocodylus siamensis* on hepatic mitochondrial function for energy homeostasis in rats, *Veterinary World*, 15(4): 986-997.

**Abstract**

**Background and Aim:** Consumption of fatty acids (FA) can alter hepatic energy metabolism and mitochondrial function in the liver. Crocodile oil (CO) is rich in mono-and polyunsaturated FAs, which have natural anti-inflammatory and healing properties. In rat livers, we investigated the effect of CO on mitochondrial function for energy homeostasis.

**Materials and Methods:** Twenty-one male Sprague-Dawley rats were divided into three groups at random. Group 1 rats were given sterile water (RO), Group 2 rats were given CO (3% v/w), and Group 3 rats were given palm oil (PO) (3% v/w). For 7 weeks, rats were given sterile water, CO, and PO orally. The researchers looked at body weight, food intake, liver weight, energy intake, blood lipid profiles, and mitochondria-targeted metabolites in the liver. The liver’s histopathology, mitochondrial architecture, and hydrolase domain containing 3 (HDHD3) protein expression in liver mitochondria were studied.

**Results:** Body weight, liver weight, liver index, dietary energy intake, and serum lipid profiles were all unaffected by CO treatment. The CO group consumed significantly less food than the RO group. The CO group also had significantly higher levels of oxaloacetate and malate than the PO group. CO treatment significantly ameliorated hepatic steatosis, as evidenced by a greater decrease in the total surface area of lipid particles than PO treatment. CO administration preserved mitochondrial morphology in the liver by upregulating the energetic maintenance protein HDHD3. Furthermore, chemical-protein interactions revealed that HDHD3 was linked to the energy homeostatic pathway.

**Conclusion:** CO may benefit liver function by preserving hepatic mitochondrial architecture and increasing energy metabolic activity.

**Keywords:** crocodile oil, energy metabolism, liver, mitochondria, rat.

**Introduction**

The liver is a metabolic biotransformation hub and plays an important role in homeostasis. Among its many functions, the liver is in charge of physiological processes such as bile production, energy generation, as well as carbohydrate, proteins, and lipids metabolism [1]. Mitochondrial dysfunction is a broad term that encompasses changes in various metabolic pathways and mitochondrial component damage. Furthermore, mitochondrial dysfunction can lead to various negative outcomes, including oxidative stress, energy deficiency, accumulation of triglycerides (steatosis), and cell death [2]. Liver steatosis is caused by an increase in adipose lipolysis, which increases hepatic *de novo* lipogenesis, impairs the synthesis and/or secretion of very-low-density cholesterol, and causes triacylglycerol esterification dysfunction, or impaired mitochondrial β-oxidation [3]. Mitochondria are unique organelles that metabolize nutrients and are responsible for energy metabolism, free radicals generation, calcium homeostasis, cell survival, and cell death [4]. Metabolic activities are supported by hepatic mitochondria, which also contribute to the pathophysiology of insulin resistance and diabetes [5,6]. The mitochondria’s primary function is to synthesize adenosine triphosphate (ATP) through oxidative phosphorylation in accordance with metabolite oxidation through the tricarboxylic acid (TCA) cycle and β-oxidation of fatty acids (FA). A previous study found that a high-fat diet alters rat hepatocyte energy metabolism by inhibiting mitochondrial oxidative phosphorylation [7].

Over the last few decades, public concerns about the interaction of health and nutrition have grown.
rapidly. Fat is a necessary macronutrient in the human diet, and vegetable oils are now the most widely consumed fat in the world. Recently, attention has been given to the association between the fatty liver condition and the type of dietary fat consumed; the previous research has linked high-saturated FA (SFA) intake to the development of hepatic steatosis [8-10], a loss of whole-body fat oxidation [11-13], and ballooned cristae, as well as condensed matrix structures of hepatic mitochondria [14]. However, certain edible cooking oils, such as olive oil, soybean oil, and palm oil (PO), are consumed in greater quantities than other higher-quality oils. PO has higher ratios of SFA to mono-unsaturated FA (MUFA) and poly-unsaturated FA (PUFA) than other cooking oils [15]. Previously, Li et al. [16] investigated the effects of a PO diet versus a low-fat diet on the expression of lipid breakdown-related genes and discovered that PO significantly reduced hepatic peroxisome proliferator-activated receptor alpha (PPAR-α) expression levels. When FAs inhibit PPARα, FA oxidation (FAO) and the resulting ATP production are reduced. Many previous studies have also linked SFA consumption to secondary diseases such as glucose intolerance, insulin resistance, dyslipidemia, cardiovascular disease, and hepatic steatosis [17-19]. Consumption of SFA-rich oils, such as PO, has been linked to the development of liver dyslipidemia, leading to mitochondrial dysfunction progression. Compared to other animal oils, crocodile oil (CO), extracted from the fatty tissues of Crocodylus siamensis, has a high concentration of MUFA and PUFA [20]. CO has been used for centuries by traditional practitioners and has been very effective in treating various ailments ranging from skin conditions to cancer [21]. CO has been used to treat skin rashes and promote wound healing in many previous studies [21,22]. Furthermore, a hamsters study found that a low MUFA and low PUFA to SFA ratio induced weight gain and body fat accumulation. In contrast, a high MUFA and high PUFA/SFA ratio prevented white adipose tissue accumulation [23]. It has been demonstrated that PUFA increases the expression of proteins involved in FAO while decreasing the expression of proteins involved in lipid synthesis [24].

However, the mechanism by which CO regulates hepatic mitochondrial-related energy metabolism in a rat model is largely unknown. We hypothesized that CO could be linked to changes in mitochondrial function in energy metabolic pathways in rat livers. As per our knowledge, this is the first report of the effect of CO on energy homeostasis via a hepatic mitochondrial function. The present study aimed to look into the effect of CO on hepatic energy metabolism and mitochondrial function in rats.

**Materials and Methods**

**Ethical approval**

The research conducted adhered to the Guidelines for the Care and Use of Laboratory Animals. The ethics committee of Kasetsart University Research and Development Institute, Kasetsart University, Thailand, approved this study (Approval No. ACKU61-VET-088).

**Study period and location**

This study was conducted from October 2019 to May 2020 at the Department of Zoology, Faculty of Science, Kasetsart University, Bangkok, Thailand.

**Animal care, diets, and experimental design**

In brief, Nomura Siam International Co. Ltd., Samutprakan province, Thailand, provided 21 Sprague-Dawley male rats (age: 7 weeks). This study used only male rats to prevent the effect of the estrous cycle on consumption behavior. The animals were individually housed in controlled environments (25±2°C on a 12-h light/12-h dark cycle). Throughout the study, rats had ad libitum access to food and water and were randomly assigned to one of three groups (n=7/group). Rats in Group 1 were given sterile water (RO), those in Group 2 were given CO (3% v/w), and those in Group 3 were given commercial PO (3% v/w) (PO). For 7 weeks, the animals were given sterile water, CO, and PO orally.

**CO preparation**

When the meat was trimmed and prepared, CO was extracted using the wet cold-pressed oil method described by Santativongchai et al. [25]. Abdominal fat samples were obtained as a waste product from slaughtered C. siamensis (age: 3-5 years) collected from a crocodile farm in Nakhon Pathom Province, Thailand. The samples were pressed through two layers of filter cloth with distilled water in a 1:1 (w/v) proportion. Following that, the solution was left undisturbed until the mixture separated. The upper clear oil fraction was then collected, evaporated, and stored at room temperature in a sealed container.

**Measurement of body weight, food intake, and energy intake of animals**

Each rat’s food intake was measured by weighing the remaining chow daily between 11:00 and 11:30 h, and this was used to calculate energy intake. The daily energy intake per rat (kcal/day) was calculated as (food intake per rat*ME from standard chow) + ME from the treatment (ME is the total energy of the rat diets, which is 3,040 kcal/g in standard chow, 12 kcal in CO per day, and 13 kcal in PO per day). Throughout the experiment, body weight was measured every week.

**Sample collection**

After the experiment, all animals were sacrificed with a lethal dose of pentobarbital sodium. Blood samples were drawn through cardiac puncture and centrifuged at 2200 g for 15 min at 4°C. The serum was kept at −20°C until further testing. The serum lipid profile was determined using a Hitachi 7080 analyzer (Hitachi, Tokyo, Japan) and included triglycerides, cholesterol, high-density lipoprotein, and low-density lipoprotein.

While performing a standard protocol for mitochondrial extraction, liver specimens were...
immediately collected, weighed to determine their index (organ weight/body weight), and stored in ice-cold homogenate buffer (0.32 M sucrose, 1 mM ethylenediaminetetraacetic acid, and 10 mM Tris-HCL; pH 7.4). Pieces of liver tissue were also separated for histopathology analysis and stored in a 10% neutral buffer formalin solution. Further liver samples were collected and homogenized in ice-cold phosphate-buffered saline (PBS) (20% w/v) before centrifugation at 2000 × g for 20 min at 4°C; the supernatants were stored at −80°C until further analysis.

Mitochondrial energy-related intermediates analysis

The frozen supernatants were mixed with methanol in a ratio of 2:8 (v/v). After centrifugation (20,000 × g for 20 min at 4°C), the supernatants were evaporated in a −80°C freeze dryer. After that, the metabolites were redissolved in 500 µL of high-performance liquid chromatography (HPLC) buffer. HPLC analysis was performed on each 5 µL sample. Chromatography was carried out in the following manner: The injection volume was set to 5 µL and the column was kept at 40°C. An InertSustain C18 (150×4.6 mm) measuring 5 µm was used to separate the mobile phase, which contained 8% 1 N sulfuric acids. Gradient elution at a flow rate of 1 mL/min was used.

Hepatic histopathology and fat accumulation analysis

Hepatocellular steatosis (macrovesicular and microvesicular) is a type of hepatotoxicity characterized by an abnormal accumulation of fat droplets in hepatocytes. Fixed livers were kept at room temperature (24-25°C) for 24 h in 10% formalin. To determine hepatocellular steatosis, the samples were embedded in paraffin, sectioned at 5-µm thickness, and stained with hematoxylin and eosin (H&E). Oil Red O (ORO) staining was used to determine the size and position of the fat droplets. Liver cryosections (5 µm thick) were fixed in PBS. They were then incubated for 1 h with 1:50 rabbit polyclonal anti-HDHD3. The frozen supernatants were mixed with methanol in a ratio of 2:8 (v/v). After centrifugation (20,000 × g for 5 min at 4°C), the supernatants were collected and centrifuged at 15,000 × g for 2 min at 4°C. The mitochondrial pellets were collected and washed in homogenate buffer several times. The pellets were resuspended in an ice-cold final equilibrated buffer (250 mM sucrose, 5 mM KH$_2$PO$_4$, 10 mM Tris-HCl, and 2 mg/mL bovine serum albumin [BSA]; pH 7.2). Subsequently, 200 µL of the resuspended pellet was fixed in 2.5% glutaraldehyde in 0.1 M sucrose phosphate buffer for electron microscopy analysis. The protein content of mitochondria was determined using a spectrophotometer (NanoDrop-1000, Thermo Scientific, Wilmington, DE, USA) and a protein assay (Bio-Rad®, Hercules, CA, USA).

Conventional electron microscopy

The ultrastructure of liver mitochondria was studied using electron microscopy. Each group’s liver specimens were fixed with 1% osmium tetroxide, dehydrated in graded ethanol, infiltrated in a series of LR white resin (EMS®, USA), embedded in pure LR white (EMS®), polymerized at 60°C for 48 h, cut into 100-nm-thick sections, and stained with lead citrate and uranyl acetate. A transmission electron microscope (model HT7700, Hitachi) was used to examine the ultrastructure of the liver. Hepatocytes with unimpaired or intact mitochondria were counted (50 cells per group) and compared with other treatment groups.

Metabolite-protein and protein-protein interaction

We used STITCH v. 5.0 (European Molecular Biology Laboratory, Heidelberg, Germany) (http://stitch.embl.de/) to predict interactions between expected metabolites and proteins that interact with the targeted mitochondrial energy-maintenance proteins (haloacid dehalogenase-like hydrolase domain containing 3: HDHD3), such as the energy-related proteins (Prkab1, Prkab2, Prkakb, Prkag1, Prkag2, Akt1, Mtor, and Raptor) (Table-1) and mitochondrial energy-related metabolites (lactate, pyruvate, alpha-ketoglutarate, oxaloacetate, citrate, and malate). STITCH also provides a confidence score for each reported interaction, with values ranging from 0.40-0.70, 0.70-0.90, and 0.90-1.00, indicating medium, high, and highest confidence levels, respectively. Our study predicted the interaction with the required confidence thresholds (scores) of 0.40 or higher.

Immunogold labeling technique

The immunogold labeling technique was used to compare HDHD3 (mitochondrial energy marker) expression and localization of mitochondria between groups. The primary antibody marker (MyBioSource, USA) was rabbit polyclonal anti-HDHD3.

The mitochondrial pellet from the pooled liver extract in each group was secondary fixed, and tissue processing was carried out as previously described. For 30 min, the tissue sections were blocked with 50 mM glycine in PBS, followed by 5% BSA (EMS®) in PBS. They were then incubated for 1 h with 1:50 diluted primary antibodies before being treated with goat anti-rabbit immunoglobulin G conjugated with
10-nm gold particles (EMS®). Sections were washed several times with 0.1% BSA in PBS between steps. After rigorously washing the tissue sections with distilled water, a silver enhancement kit (Aurion R-Gent SE-EM kit; EMS®) was used to improve the contrast of the gold particle labeling. Finally, the sections were stained with lead citrate and uranyl acetate before transmission electron microscopy. The number of labeled gold particles was counted to determine the intact stage of liver mitochondria (50 mitochondria/group was evaluated).

**Statistical analysis**

To better understand the biological processes, the targeted energy-related proteins (Prkaa1, Prkaa2, Prkab1, Prkab2, Prkag1, Prkag2, Akt1, Mtor, and Raptor) were identified using the NCBI and UniProt databases.

The data are presented as mean±standard error of the mean. Statistical analysis was performed by one-way analysis of variance followed by Tukey’s post hoc test in the R project statistical computing package (R core team, 2019). p<0.05 was considered statistically significant.

**Results**

**Effect of dietary CO on final body weight, body weight gain, liver index, food intake, and energy intake**

As shown in Table-2, CO- and PO-treated rats consumed significantly less food (15.84±0.28 and 14.98±0.31 g/day, respectively) than the RO group (18.82±0.25 g/day). However, there were no significant differences between groups in terms of final body weight, body weight gain, liver index, or energy intake.

**Effect of dietary CO on blood lipid profiles and liver mitochondrial energy-related metabolites**

Figure-1 depicts serum lipid profiles. The results revealed no statistically significant differences between the three groups. Interestingly, when compared to the RO group (138.25±30.14 mg/dL), both the CO (90.40±15.14 mg/dL) and PO (83.68±6.44 mg/dL) groups showed a decreasing trend in triglyceride levels.

Figure-2 shows that the CO-treated group had significantly higher hepatic oxaloacetate levels (17.90±0.53 mg/L) than the RO- and PO-groups (13.17±0.45 and 14.37±0.53 mg/L, respectively).

### Table-1: Targeted energy metabolic-related protein list according to UniProt database.

| Protein names                                      | Gene names          | Mass   | Gene ontology (biological process)                                      |
|----------------------------------------------------|---------------------|--------|-------------------------------------------------------------------------|
| 5’-AMP-activated protein kinase catalytic subunit alpha-1 (AMPK subunit alpha-1) | Prkaa1             | 63,973 | CAMKK:AMPK signaling cascade [GO: 0061762]                               |
| 5’-AMP-activated protein kinase catalytic subunit alpha-2 (AMPK subunit alpha-2) | Prkaa2             | 62,258 | Energy homeostasis [GO: 0097009]                                        |
| 5’-AMP-activated protein kinase catalytic subunit beta-1 (AMPK subunit beta-1) | Prkb1              | 30,394 | Energy homeostasis [GO: 0097009]                                        |
| 5’-AMP-activated protein kinase catalytic subunit beta-2 (AMPK subunit beta-2) | Prkb2              | 30,227 | Regulation of catalytic activity [GO: 0050790]                         |
| 5’-AMP-activated protein kinase catalytic subunit gamma-1 (AMPK subunit gamma-1) | Prkag1             | 37,386 | Regulation of primary metabolic process [GO: 0080090]                   |
| Protein kinase AMP-activated non-catalytic subunit gamma 2 | Prkag2             | 62,984 | Regulation of catalytic activity [GO: 0050790]                         |
| RAC-alpha serine/threonine-protein kinase (Protein kinase B) | Akt1               | 55,735 | Regulation of fatty acid metabolic process [GO: 0019217]                 |
| Serine/threonine-protein kinase mTOR (Mammalian target of rapamycin) | Mtor, Raft1 | 288,794 | Glucose homeostasis [GO: 0042593]; positive regulation of mitochondrial membrane potential [GO: 0010918]; protein kinase B signaling [GO: 0043491] | Energy reserve metabolic process [GO: 0006112]; Regulation of fatty acid beta-oxidation [GO: 0031998]; Response to nutrient levels [GO: 0031667]; TOR signaling [GO: 0031929] |

### Table-2: Effect of dietary crocodile oil on final body weight, body weight gain, liver weight, liver index, average food intake, and average energy intake of rats for 7 weeks.

| Group        | Final body weight (g) ± SE | Body weight gain (g) ± SE | Liver weight (g) ± SE | Liver index (g) ± SE | Food intake (g/day) ± SE | Energy intake (kcal/day) ± SE |
|--------------|----------------------------|---------------------------|-----------------------|----------------------|--------------------------|-----------------------------|
| RO           | 522.57±19.25               | 26.17±2.67                | 12.45±0.69            | 0.024±0.00058        | 18.82±0.25               | 57.21±0.78                   |
| Crocodile oil| 534.43±5.98                | 33.86±5.80                | 13.67±0.72            | 0.026±0.0013         | 15.84±0.28               | 60.16±0.86                   |
| Palm oil     | 528.86±19.51               | 34.67±4.54                | 13.34±0.59            | 0.026±0.00075        | 14.98±0.31               | 58.53±0.95                   |

Data are expressed as the mean±standard error of the mean. Different letters indicate statistically significant differences between groups (p<0.05).
Available at www.veterinaryworld.org/Vol.15/April-2022/24.pdf

Meanwhile, there was no difference in hepatic malate levels between the CO and RO groups (246.92±6.02 and 258.03±6.72 mg/L, respectively), but the CO group had a significantly higher malate level than the PO group (204.41±6.61 mg/L) (Figure-2f). On the other hand, CO administration did not affect lactate, pyruvate, citrate, or alpha-ketoglutarate levels in the liver (Figure-2a-c, and e).

**Effect of dietary CO on hepatic lipid accumulation**

H&E staining was used to visualize hepatic steatosis in liver sections at 200× and 400× magnifications. Compared to the livers of RO-treated rats, liver histologic examination revealed microvesicular deposition (numerous small vesicles of fat in hepatocytes) in CO- and PO-treated rats. The size of fat droplets in CO, on the other hand, was clearly smaller than in PO. Furthermore, macrovesicular steatosis (a single large vacuole of fat filling up the hepatocyte) was found in the PO group, whereas the CO group showed had microvesicular steatosis (Figure-3a-f). The number and size of hepatic fat droplets were lower in the RO group than in the CO and PO groups. Meanwhile, as shown in Figure-3j, the CO group had a significantly lower total surface area of lipid droplets in the liver than the PO group (608.40±35.67 and 889.23±44.77 µm², respectively). The total lipid particle area seen in CO-treated rats, on the other hand, was significantly greater than that seen in RO-treated rats (391±40.67 µm²).

**Effect of CO on mitochondrial architecture and expression of HDHD3 in liver mitochondria**

After 7 weeks of CO administration, electron microscopy analysis was performed. The CO-treated rats had a similar percentage of intact mitochondria (65.71%) as the control RO group (64.45%), but significantly higher than the PO-treated rats (43.96%) (Figure-4). The expression of HDHD3, an energy-maintenance protein, was chosen to test their activity in the intact stage of mitochondria. The CO group had significantly higher levels of mitochondrial HDHD3 expression (2.86±0.52 gold particle/mitochondria) than the PO group (1.39±0.23 gold particle/mitochondria). Meanwhile, when compared with the CO and PO groups, the expression of HDHD3 protein was significantly higher in the RO group (4.98±0.40 gold particle/mitochondria) (Figure-5).

**Figure-1:** Effect of dietary crocodile oil on serum (a) cholesterol, (b) triglyceride, (c) low-density cholesterol, and (d) high-density cholesterol levels of rats for 7 weeks. Data are expressed as the mean±standard error of the mean.

**Figure-2:** Effect of dietary crocodile oil on liver mitochondrial energy related-metabolites (a) lactate, (b) pyruvate, (c) citrate, (d) oxaloacetate, (e) alpha-ketoglutarate, and (f) malate levels. Data are expressed as the mean±standard error of the mean. Different letters indicate statistically significant differences between groups (p<0.05).
The chemical-protein and protein-protein interaction analysis

The interaction network revealed that the HDHD3 protein was linked to the energy homeostatic pathway in the liver, as shown in Figure-6. HDHD3 interacted with chemicals and proteins in the mammalian target of rapamycin (mTOR) pathway (rapamycin; score=0.641), and the AMP-activated protein kinase (AMPK) signaling pathway (Prkag1; score=0.427, and Prkag2; score=0.469), both of which are energy regulatory pathways. Furthermore, HDHD3 interacted with energy-related metabolites (lactate; score=0.867) and was linked to ATP metabolic processes (ATP; score=0.696). In tabular form, the interaction score between HDHD3 and the energy-related target was shown (Supplementary Table-1).

Meanwhile, the three most abundant FAs in CO (linoleic acid [LA], oleic acid [OA], and palmitic acid) interacted favorably with other chemicals involved in hepatic energy metabolism and proteins involved in the AMPK signaling pathway. As a result, CO can improve the activity of energy metabolism in the liver by upregulating the mitochondrial protein, HDHD3.

Discussion

Our study is the first to look at the effect of CO on the changes in the health status of energy metabolism and mitochondrial function in the liver after 7 weeks of treatment. When compared to the PO group, CO could increase some key metabolites during mitochondrial energy metabolism, decrease hepatic steatosis, improve liver mitochondrial architecture, and
upregulate energy-maintenance protein expression. These findings suggest that CO administration may be beneficial in the treatment of clinical liver metabolic damage. Meanwhile, there were no differences in final body weight, body weight gain, or energy intake between groups of CO-treated rats. We discovered that the primary MUFA and PUFA in CO were OA and LA, respectively. One of the essential FAs for humans and

**Figure-4:** Comparison of electron micrographs of hepatic mitochondria conformation among the RO (a), crocodile oil (b), and palm oil (c) groups. The bar graph indicates the percentage of intact mitochondria (d), data are represented by mean±standard error of the mean. Different letters indicate statistically significant differences between groups (p<0.05). Scale bars=2 µm.

**Figure-5:** Comparison of the HDHD3 immunogold labeling at the intact stage of hepatic mitochondria among the RO (a), crocodile oil (b), and palm oil (c) groups. The bar graph indicates the level of gold particles in HDHD3 labeling (d); data are represented by mean±standard error of the mean. Different letters indicate statistically significant differences between groups (p<0.05). Scale bars=200 nm. Blue arrows indicate a number of HDHD3-labeled gold particles.
other mammals is PUFA. According to a previous study, PUFAs play an important role in the composition of all cell membranes, where they maintain homeostasis for proper membrane protein function and influence membrane fluidity, thereby regulating cell signaling processes, cellular functions, and gene expression [26]. In this regard, we agreed that CO consumption could have a protective effect on energy mitochondrial function.

First, our findings showed that an intake of dietary oil (CO and PO) was associated with lower food intake and higher fat accumulation in hepatocytes when compared to the RO group. A previous study looked at dietary FAs (SFA, MUFA, or PUFA) and found that they had a physiological effect on energy expenditure, energy intake, and body weight control [27]. The previous research on the effect of fat saturation on satiety and food intake reports that unsaturated FA-containing fats reduce food intake more than stearic acid-containing fats [28]. Furthermore, the current study found that PO, which is rich in SFA (palmitic acid), reduced food intake compared to the RO group. Many previous studies agree that SFA sources containing palmitic acid (coconut oil and palm kernel oil) provide greater satiety than other fat sources [29,30]. However, we propose no difference in food ingestion responses between types of dietary fat; this finding necessitates additional research into the mechanism by which saturation level can regulate food consumption and body weight management. On the other hand, the results showed that both types of dietary fat increased hepatic lipid accumulation compared to the RO group. It is widely accepted that dietary FA composition is an important determinant of hepatic lipid metabolism. In this context, a previous study found that increasing FAs in the diet, particularly SFA, played a significant role in the development of hepatic fat accumulation [31].

PO, which is rich in SFA like palmitic acid, increased fat accumulation in hepatocytes and induced mitochondrial dysmorphology in this study. The previous studies have linked abnormalities in mitochondrial morphology and function to fatty liver accumulation [32,33]. This point could contribute to the decrease in energy metabolism and mitochondrial function. PO is currently the most widely used edible oil in the food industry, although its relationship with liver energy metabolism remains unknown. Our current findings of H&E and ORO staining of lipid droplets in hepatocytes of rats fed PO revealed large
lipid droplet size as macrovesicular steatosis and significantly increased surface area of intrahepatic triglycerides compared with the RO and CO groups, with CO exhibiting higher levels of liver content than the RO group. We propose that while the CO diet influences fat accumulation more than the normal rat diet, it may also prevent the development of lipid accumulation in the liver compared with the PO diet. The previous research has suggested that SFA may play a role in lipid metabolic toxicity, such as oxidative stress, and mitochondrial dysfunction [34]. PO altered hepatic metabolism and caused lipid accumulation via disturbed hepatocyte transcription, according to the previous study [35]. A subsequent study found that SFA sources containing palmitic acid can activate NOD-like receptor family pyrin containing 3 (NLRP3) inflammasomes, which are linked to the development of liver steatosis [36]. Meanwhile, Li et al. [16] investigated the effects of PO and a low-fat diet on the expression of lipid breakdown-related genes. The PO-treated group had significantly lower levels of expression of the PPAR-α (the gene involved in FAO), FA transport proteins, and their derivatives entering into the β-oxidation pathway to control energy homeostasis [37]. However, previous research has shown that olive oil, which is rich in MUFA, reduces liver fat accumulation by improving insulin resistance and increasing triglyceride release from the liver [38]. A subsequent study found that PUFA can reduce intracellular triglyceride deposition in the liver [39], and act as a potent inhibitor of hepatic lipogenesis [40]. As previously stated, a dietary CO, rich in MUFA (OA) and PUFA (LA), or PO, rich in SFA (palmitic acid) has a distinct effect on liver metabolism and hepatic fat accumulation because PO causes a significant increase in liver fat when compared to CO. PO, we believe, triggers energy metabolic deficiency by downregulating the transcription of energy homeostatic genes and causes liver damage by impairing mitochondrial function. It should come as no surprise that mitochondrial dysfunction plays a significant role in the development of excessive hepatic fat accumulation following PO administration.

Mitochondrial energy-related-metabolite levels reflect liver cell energy homeostasis. Our findings show that PO administration causes a decrease in some key energy-related metabolite levels. In contrast, CO administration causes a significant increase in oxaloacetate and malate levels in the TCA cycle compared to PO administration. The TCA cycle is the cell’s central metabolic hub and an important source of precursors for energy supply. However, the effects of CO on energy metabolism are not completely understood. Interestingly, according to a previous study, MUFA (OA) and PUFA (LA) are broken down in mitochondrial to produce acetyl-CoA through FAO, a metabolite product that enters the TCA cycle to maintain ATP [41]. Furthermore, Liu et al. [42] investigated the mechanism by which omega-3 PUFA influences the TCA cycle in obesity; they discovered that PUFA may alleviate obesity by affecting mitochondrial function and restoring TCA cycle homeostasis, specifically the transcription and translation of TCA cycle enzymes such as citrate synthase, succinate dehydrogenase subunits A (SDHA), fumarate hydratase, and malate dehydrogenase 2 (MDH2) in HepG2 cells. Meanwhile, a recent study on the effect of SFA supplementation on the architecture and protein expression patterns of the murine heart discovered that protein expression patterns in animals fed a high-SFA diet show impairment of the TCA cycle and ATP synthesis [43]. Thus, PUFA-enriched diets could stimulate energy metabolic activity in rats by activating genes involved in the production of energy mitochondrial-related intermediates.

We observed the liver mitochondrial morphology and expression levels of proteins related to energy homeostasis to investigate the possible mechanisms of CO for the improvement of liver mitochondrial function. The current study’s findings revealed that PO had fewer healthy mitochondria than the CO and RO treatments. According to a previous study, a high-SFA diet caused hepatic fat accumulation which was consistent with impaired mitochondrial function and a dysregulated expression profile of mitochondrial dynamic proteins [44]. Furthermore, a high-SFA diet high in lard was linked to lower energy expenditure and the expression of genes controlling lipid metabolism and mitochondrial function [45]. Furthermore, the previous study in skeletal muscle cells has found that palmitic acid, the main SFA in PO, has a proclivity to induce mitochondrial DNA damage [46], as well as changes in mitochondrial morphology and function [47]. As a result, PO may contribute to mitochondrial form and function changes, leading to the development and progression of energy metabolic dysfunction in the liver. In contrast, according to our findings, CO-treated rats had a significantly higher percentage of intact mitochondria than the PO-treated group. Although there was little evidence of the effect of CO on mitochondrial function, studies on the effect of MUFA and PUFA on mitochondrial function were moderately published. According to a recent study on the effect of OA (the main MUFA of CO) on mitochondrial homeostasis at a cellular level, MUFA modulates mitochondrial function and lipid metabolism [48,49], resulting in increased mitochondrial ATP production. Furthermore, a previous study discovered that MUFA and PUFA inhibit the pro-inflammatory action of excess palmitic acid and counteract the morphological and functional changes in mitochondria [50]. Importantly, animals studies and a steatotic hepatocyte model support our hypothesis that PUFA improves mitochondrial morphology and has a beneficial effect on mitochondrial function recovery by regulating the mammalian target of the rapamycin complex 1 (mTORC1) pathway [51,52]. Previous research indicates that mTOR primarily acts through mTORC1, reducing oxidative capacity and altering mitochondrial morphology [53]. Many studies indicate that MUFA
and PUFA intake have beneficial effects on mitochondrial dysmorphic features; these findings support our findings that CO restores liver energy metabolism by maintaining mitochondria ultrastructure and function.

Our current findings also confirmed CO’s protective effect on energy homeostasis; we discovered that CO not only maintains mitochondrial morphology but also increases energy production in the liver by upregulating mitochondrial HDHD3 protein. HDHD3 has been identified as a mitochondrial protein involved in cell energy maintenance [54]. The protein HDHD3 was found to be downregulated in PO-treated rats, whereas it was found to be upregulated in the CO-treated group. The interaction network between the HDHD3 and other predictable proteins involved in energy metabolism (Akt1, Prkaa1, Prkaa2, Prkb1, Prkb2, Prkg1, Prkg2, Mtor, and Raptor) were examined using the STITCH database (Figure-6). HDHD3 proteins were discovered to be associated with the protein kinases AMP-activated non-catalytic subunit gamma 1 (Prkg1), protein kinases AMP-activated non-catalytic subunit gamma 2 (Prkg2), and ATP production. Prkg1 and Prkg2 encode two isoforms of the AMPK γ chain. AMPK is a key energy-sensing enzyme that monitors cellular energy status and has dual effects on mitochondrial function and structure [55]. Consuming PUFA-rich oil may increase hepatic AMPK activity and influence the regulation of hepatic lipid metabolism and gene expression [56].

Similarly, a previous study on the effects of krill oil (enriched with PUFA) on liver function found that the oil regulates genes and pathways involved in hepatic energy metabolism [57]. AMPK activation also causes mitochondrial biogenesis [58-60]. Mitochondrial biogenesis occurs in response to mitochondrial dysfunction in the liver to maintain cellular homeostasis against oxidative stress and injury by forming new mitochondria [61]. Surprisingly, our protein network result revealed a strong relationship between HDHD3, rapamycin, and an intermediate of mitochondrial energy metabolism. Rapamycin is an effective inhibitor of the mTOR protein kinase, which functions as a key integrator of nutrient signaling pathways [62]. mTOR promotes anabolic processes such as protein synthesis and is a key regulator of energy production in mitochondria [63], particularly TCA cycle intermediate production of mitochondrial metabolism. Furthermore, previous research found that inhibiting mTOR decreased levels of five key TCA cycle intermediates [63,64]. We believe that consuming PUFA-rich oil has a one-of-a-kind ability to improve energy metabolic associated mitochondrial structure and function. Finally, this research revealed that CO could improve liver energy homeostasis and mitochondrial contents by activating the mitochondrial HDHD3 protein.

**Conclusion**

As per our knowledge, this is the first report of the effect of CO on energy homeostasis via a hepatic mitochondrial function. Our findings add to our understanding of the long-term effect of CO consumption on hepatic energy metabolism and mitochondrial function. Compared to the normal range, CO treatment reduced food intake and some key hepatic energy metabolite levels. It also slowed the progression of hepatic steatosis, improved mitochondrial morphology, and played an important role in energy metabolism maintenance by upregulating HDHD3 expression. Through the expression of protein-associated metabolic homeostasis, our findings may have clinical and therapeutic implications. CO has the potential to be a viable dietary fat substitute as well as a good choice for an economical therapeutic agent for treating metabolic energy disorders in the future.

**Authors’ Contributions**

KP: Performed the study, analyzed the data, and wrote the manuscript. KS and PS: Performed the experiments. UP: Performed histological analysis. SA: Provided and analyzed mitochondrial function, and edited the manuscript. PT: Resource, conceptualization and revised the manuscript. WF: Conceived, designed, supervised the study and edited the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This study was funded by the Department of Zoology, Faculty of Science and partially supported by the Faculty of Veterinary Medicine, Kasetsart University, Thailand. The Science Achievement Scholarship of Thailand supported the scholarship and fund for laboratory equipment without the grant number. A preprint has been published on the research square [65].

**Competing Interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Veterinary World remains neutral with regard to jurisdictional claims in published institutional affiliation.

**References**

1. Vargas-Mendoza, N., Madrigal-Santillán, E., Morales-González, A., Esquivel-Soto, J., Esquivel-Chirino, C., García-Luna Y González-Rubio, M., Gayoso-de-Lucio, J.A. and Morales-González, J.A. (2014) Hepatoprotective effect of silymarin. World J. Hepatol., 6(3): 144-149.
2. Begriche, K., Massart, J., Robin, M.A., Borgne-Sanchez, A. and Fromenty, B. (2011) Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J. Hepatol., 54(4): 773-794.
3. Kawano, Y. and Cohen, D.E. (2013) Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J. Gastroenterol., 48(4): 434-441.
4. Kim, J.A., Wei, Y. and Sowers, J.R. (2008) Role of mitochondrial dysfunction in insulin resistance. Circ. Res., 102(4): 401-414.
5. Jelenik, T. and Roden, M. (2013) Mitochondrial plasticity
in obesity and diabetes mellitus. *Antioxid. Redox Signal.*, 19(3): 258-268.

6. Hesselink, M.K., Schrauwenn-Hindler, V. and Schrauwenn, P. (2016) Skeletal muscle mitochondria as a target to prevent or treat Type 2 diabetes mellitus. *Nat. Rev. Endocrinol.*, 12(11): 633-645.

7. Vial, G., Dubouchaud, H., Couturier, K., Cottet-Rousselie, C., Taleux, N., Athias, A., Galinier, A., Castellini, E. and Leverve, X.M. (2011) Effects of a high-fat diet on energy metabolism and ROS production in rat liver. *J. Hepatol.*, 54(2): 348-356.

8. Sobrecases, H., Lé, K.A., Bortolotti, M., Schneiter, P., Ith, M., Kreis, R., Boesch, C. and Tappy, L. (2010) Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. *Diabetes Metab.*, 36(3): 244-246.

9. Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.E., Larsson, A., Johansson, L., Ahlström, H., Amer, P., Dahlman, I. and Risérus, U. (2014) Overfeeding polysaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans. *Diabetes*, 63(7): 2356-2368.

10. Rosqvist, F., Kullberg, J., Ståhlman, M., Cedernaes, J., Heurling, K., Johansson, H.E., Iggman, D., Wilking, H., Larsson, A., Eriksson, O., Johansson, L., Straniero, S., Rudling, M., Antoni, G., Lubberink, M., Borén, J., Ahlström, H. and Risérus, U. (2019) Overeating saturated fat promotes fatty liver and ceramides compared with polysaturated fat: A randomized trial. *J. Clin. Endocrinol. Metab.*, 104(12): 62076219.

11. Jones, P.J., Pencharz, P.B. and Clodin, M.T. (1985) Whole body oxidation of dietary fatty acids: Implications for energy utilization. *Am. J. Clin. Nutr.*, 42(5): 769-77.

12. Jones, P.J. and Schoeller, D.A. (1988) Polysaturated: Saturated ratio of diet fat influences energy substrate utilization in the human. *Metabolism*, 37(2): 145-151.

13. DeLany, J.P., Windhauser, M.M., Champagne, C.M. and Bray, G.A. (2000) Differential oxidation of individual dietary fatty acids in humans. *Am. J. Clin. Nutr.*, 72(4): 905-911.

14. Simões, I.C.M., Fontes, A., Pinton, P., Zischka, H., Parmentier, M. (2007) Fatty acid profiles of 80 vegetable oils with regard to their nutritional potential. *Eur. J. Lipid Sci. Technol.*, 109(7): 710-732.

15. Li, Y., Xu, Y., Yu, J., Li, D., Lu, Q., Cao, P. and Liu, Y. (2020) Effects of polar compounds in fried palm oil on liver lipid metabolism in C57 mice. *J. Food Sci.*, 85(6): 915-1923.

16. Kabbabin, E-L., Sullivan, S. and Klein, S. (2010) Obesity and non-alcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. *Hepatology*, 51(2): 679-689.

17. Heinrichsen, E.T., Zhang, H., Robinson, J.E., Ngo, J., Diop, S., Bodmer, R., Joiner, W.J., Metallo, C.M. and Haddad, G.G. (2013) Metabolic and transcriptional response to a high-fat diet in *Drosophila melanogaster*. *Mol. Metab.*, 3(1): 42-54.

18. McDardle, M.A., Finucane, O.M., Connaughton, R.M., McMorrow, A.M. and Roche, H.M. (2013) Mechanisms of obesity-induced inflammation and insulin resistance: Insights into the emerging role of nutritional strategies. *Front. Endocrinol. (Lausanne)*, 4: 52.

19. Gunstone, F.D. and Russell, W.C. (1954) Animal fats. The component acids of crocodile fat. *Biochem. J.*, 57(3): 462-465.

20. Buthelezi, S., Southway, C., Govinden, U., Bodenstein, J. and du Toit, K. (2012) An investigation of the antimicrobial and anti-inflammatory activities of crocodile oil. *J. Ethnopharmacol.*, 143(1): 325-330.

21. Li, H.L., Chen, L.P., Hu, Y.H., Qin, Y., Liang, G., Xiong, Y.X. and Chen, Q.X. (2012) Crocodile oil enhances cutaneous burn wound healing and reduces scar formation in rats. *Acad. Emerg. Med.*, 19(3): 265-273.

22. Liao, F.H., Liou, T.H., Shieh, M.J. and Chien, Y.W. (2010) Effects of different ratios of monounsaturated and polynsaturated fatty acids to saturated fatty acids on regulating body fat deposition in hamsters. *Nutrition*, 26(7-8): 811-817.

23. Clarke, S.D. (2001) Non-alcoholic steatosis and steato-hepatitis. I. Molecular mechanism for polysaturated fatty acid regulation of gene transcription. *Am. J. Physiol. Gastrointest. Liver. Physiol.*, 281(4): G865-G869.

24. Samtawngvee, W., Pungfoun, W., Boonyawisit, V., Pongchairerk, U. and Tulayakul, P. (2020) Comparison of physicochemical properties and fatty acid composition of crocodile oil (*Crocodylus siamensis*) extracted by using various extraction methods. *Int. J. Food Properties*, 23(1): 1465-1474.

25. Das, U.N. (2006) Essential fatty acids: Biochemistry, physiology and pathology. *Biotechnol. J.*, 14(4): 420-439.

26. Wang, D.D. and Hu, F.B. (2017) Dietary fat and risk of cardiovascular disease: Recent controversies and advances. *Annu. Rev. Nutr.*, 37: 423-446.

27. Maljaars, J., Romeyn, E.A., Haddeman, E., Peters, H.P. and Maslce, A.A. (2009) Effect of satiety on satiety, hormone release, and food intake. *Am. J. Clin. Nutr.*, 89(4): 1019-1024.

28. Alfenas, R.C. and Mattes, R.D. (2003) Effect of fat sources on satiety. *Obes. Res.*, 11(2): 183-187.

29. Kozimor, A., Chang, H. and Cooper, J.A. (2013) Effects of dietary fatty acid composition from a high fat meal on satiety. *Appetite*, 69: 39-45.

30. Leamy, A.K., Egnatchik, R.A. and Young, J.D. (2013) Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. *Prog. Lipid. Res.*, 52(1): 165-174.

31. Rovés, P.M. and Fernandez-Checa, J.C. (2013) Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance. Cause or consequence? *Free Radic. Res.*, 47(11): 854-868.

32. Begriche, K., Massart, J., Robin, M.A., Bonnet, F. and Fromenty, B. (2013) Mitochondrial adaptations and dysfunctions in non-alcoholic fatty liver disease. *Hepatology*, 58(4): 1497-1507.

33. Tariq, Z., Green, C.J. and Hodson, L. (2014) Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? *Liver. Int.*, 34(7): e180-e190.

34. Sales, R.C., Medeiros, P.C., Sprefico, F., de Velasco, P.C., Gonçalves, F., Martin-Hernández, R., Mantilla-Escalante, D.C., Gil-Zamorano, J., Peres, W., de Souza, S., Dávalos, A. and Tavares do Carmo, M.G. (2018) Olive oil, palm oil, and hybrid palm oil distinctly modulate liver transcriptome and induce NAFLD in mice fed a high-fat diet. *Int. J. Mol. Sci.*, 20(1): 8.

35. Zhu, W., Feng, P.P., He, K., Li, S.W. and Gong, J.P. (2018) Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. *Biochem. Biophys. Res. Commun.*, 505(2): 523-529.

36. Feingold, K.R., Wang, Y., Moser, A., Shigenaka, J.K. and Grunfeld, C. (2008) LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. *J. Lipid. Res.*, 49(10): 2179-2187.

37. Hussein, O., Grosof, M., Lasri, E., Svalb, S., Ravid, U. and Assay, N. (2007) Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. *World. J. Gastroenterol.*, 13(3): 361-368.

38. Di Minno, M.N., Russolillo, A., Lupoli, R., Ambrosino, P., Di Minno, A. and Tarantino, G. (2012) Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. *World J. Gastroenterol.*, 18(4): 5839-5847.

39. Jump, D.B. (2011) Fatty acid regulation of hepatic lipid metabolism. *Curr. Opin. Clin. Nutr. Metab. Care*, 14(2): 115-120.

40. Han van der Kolk, J.H., Gross, J.J., Gerber, V. and Bruckmaier, R.M. (2017) Disturbed bovine mitochondrial lipid metabolism: A review. * Vet. Q.*, 37(1): 262-273.
Supplementary Table

**Supplementary Table-1:** Confidence score of chemical-protein and protein-protein interaction between HDHD3 and energy-related targets according to STITCH database.

| Node 1  | Node 2  | Node 1 accession | Node 2 accession | Confidence score |
|--------|--------|------------------|------------------|------------------|
| Hdh3   | Prkg1  | ENSRNOP00000020380 | ENSRNOP0000002093 | 0.427            |
| Hdh3   | Prkg2  | ENSRNOP00000020380 | ENSRNOP0000062361 | 0.469            |
| Hdh3   | rapamycin | ENSRNOP00000020380 | 5040            | 0.641            |
| Hdh3   | MgATP | ENSRNOP00000020380 | 238             | 0.696            |
| Hdh3   | lactate | ENSRNOP00000020380 | 612             | 0.867            |

Available at www.veterinaryworld.org/Vol.15/April-2022/24.pdf

Veterinary World, EISSN: 2231-0916, 997

Liu, R., Chen, L., Wang, Z., Zheng, X., Hou, Z., Zhao, D., Long, J. and Liu, J. (2021) Omega-3 polyunsaturated fatty acids prevent obesity by improving tricarboxylic acid cycle homeostasis. *J. Nutr. Biochem.*, 88:108503. DOI:10.1016/j.jnutbio.2020.108503.

Lepeżyński, A., Ozgo, M., Michalek, K., Drawa-Chałupnik, A., Grabowska, M., Herosimczyk, A., Liput, K.P., Polańska, E., Kram, A. and Pierzchala, M. (2021) Effects of three-month feeding high-fat diets with different fatty acid composition on myocardial proteome in mice. *Nutrients*, 13(2): 330.

Lionetti, L., Mollica, M.P., Donizzetti, I., Gifuni, G., Sica, R., Pignalosa, A., Cavaliere, G., Maita, M., De Filippo, C., Zorzano, A. and Potti, R. (2014) High-lard and high-fish-oil diets differ in their effects on function and dynamic behaviour of rat hepatic mitochondria. *PLoS One*, 9(3): e92733.

Choi, M.S., Kim, Y.J., Kwon, E.Y., Ryoo, J.Y., Kim, S.R. and Jung, U.J. (2015) High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling and inflammation-related genes. *Br. J. Nutr.*, 113(6): 867-877.

Uzefovych, L.V., Solodushko, V.A., Wilson, G.L. and Rachek, L.I. (2012) Protection from palmitate-induced mitochondrial DNA damage prevents from mitochondrial oxidative stress, mitochondrial dysfunction, apoptosis, and impaired insulin signaling in rat L6 skeletal muscle cells. *Endocrinology*, 153(1): 92-100.

Kucharska, G., Tekle, M., Saha, A.K., Ruderman, N.B., Clarke, S.D. and Gettys, T.W. (2005) Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats. *Biochem. Biophys. Res. Commun.*, 326(4): 851-858.

Burri, L., Berge, K., Wiibrand, K., Berge, R.K. and Barger, J.L. (2011) Differential effects of krill oil and fish oil on the hepatic transcriptome in mice. *Front. Genet.*, 2:45.

Cántó, C. and Auswerx, J. (2009) PGC-1α and AMPK, an energy sensing network that controls energy expenditure. *Curr. Opin. Lipidol.*, 20(2): 98-105.

Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M. and Spiegelman, B.M. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell*, 92(6): 829-839.

Kelly, D.P. and Scarpulla, R.C. (2004) Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. *Genes Dev.*, 18(4): 357-368.

Peterson, Y.K., Cameron, R.B., Wills, L.P., Trager, R., Lindsey, C.C., Beeson, C.C. and Schnellmann, R.G. (2013) β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis. *Bioorg. Med. Chem. Lett.*, 23(19): 5376-5381.

Lamming, D.W. (2016) Inhibition of the mechanistic target of rapamycin (Mtor)-rapamycin and beyond. *Cold Spring Harb. Perspect. Med.*, 6(5): 025924.

Morita, M., Gravel, S.P., Chénard, V., Sikström, K., Zheng, L., Alain, T., Gandin, V., Avizonis, D., Arguello, M., Zakaria, C., McLaughlan, S., Nonet, Y., Pauæ, A., Pollak, M., Gottlieb, E., Larsson, O., St-Pierre, J., Topisirovic, I. and Sonenberg, N. (2013) mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. *Cell Metab.*, 18(5): 698-711.

Ramanathan, A. and Schreiber, S.L. (2009) Direct control of mitochondrial function by mTOR. *Proc. Natl. Acad. Sci. U. S. A.*, 106(52): 22229-22232.

Parunyakul, P., Srisuksai, K., Santativongchai, P., Pongchairerk, U., Ampawong, S., Tulayakul, P. and Fungfuang, W. (2021) The Effect of Crocodile (*Crocodylus siamensis*) Oil on Hepatic Energy Homeostasis Mechanism and Mitochondrial Function in Rats. Research Square, August 18, 2021.